Quarterly report pursuant to Section 13 or 15(d)

CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)

v3.4.0.3
CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Consolidated Statements Of Operations    
Revenues
Operating expenses:    
Amortization & depreciation $ 184
General and administrative $ 98,011 85,271
Total operating expenses 98,011 85,455
Loss from operations (98,011) (85,455)
Other income (expense):    
Gain on non-related party share issuances $ 2,250 0
Gain (Loss) on fair value adjustment - derivatives 25,456
Interest expense $ (64,212) (55,414)
Interest expense - beneficial conversion feature (6,250) (3,750)
Total other income (expense) (68,212) (33,708)
Loss before provision for income taxes $ (166,223) $ (119,163)
Provision for income tax
Net loss $ (166,223) $ (119,163)
Less: Net loss attributable to noncontrolling interest 1,071 934
Net loss attributable to TranBioTec, Inc. $ (165,152) $ (118,229)
Net loss per share    
(Basic and fully diluted) $ (0.003) $ (0.003)
Weighted average number of common shares outstanding 66,020,299 39,215,919